

AlzeCure presents positive preclinical efficacy data for the TrkA-NAM pain project

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company has received positive preclinical in vivo effect data for the pain project TrkA-NAM.

AlzeCure's preclinical pain project TrkA-NAM is based on the company's research platform Painless and focuses on the treatment of severe pain conditions, such as osteoarthritis of the joints. In a recently completed in vivo efficacy study, TrkA-NAM has shown positive effects in a preclinical pain model.

"We are very happy to be able, as promised, to present effect data from our exciting pain project TrkA-NAM. The results are promising, even though they are in a preclinical stage, and I am very much looking forward to the continued development of the project," said Martin Jönsson, CEO of AlzeCure Pharma AB.

"Just like our other projects in the CNS field, TrkA-NAM is focused on an area where there is a great need for more effective treatments. There is also a great demand in the pain area to be able to replace opioids, which initiate addiction problems. There are today an estimated 250 million patients suffering from osteoarthritis and a great need for more effective and tolerable drugs as an alternative to today's existing treatments, which mainly consist of opioids or NSAIDs. The great market potential in severe pain conditions such as osteoarthritis, together with the fact that TrkA-NAM is based on a biological mechanism with strong preclinical and clinical validation, has meant that we have already seen great interest from potential partners".

The objective of the TrkA-NAM pain project is to develop a TrkA-Negative Allosteric Modulator (NAM) that can reduce movement-induced and spontaneous pain in patients with severe pain conditions. The target mechanism has strong preclinical and clinical validation, and AlzeCure's unique compounds aim to differentiate from antibody treatments with their selective effect on the relevant signaling pathway so that optimal analgesic effect can be achieved without inducing side effects.

In addition, the TrkA-NAM compounds are small molecules, which both facilitates administration for the patient (tablet form) while also contributing to a more cost-effective treatment.

For more information, please contact

Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com

About AlzeCure Pharma AB (publ)

AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain – indications for which currently available treatment is extremely limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of three symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. Alzstatin comprises two disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a clinical candidate for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase and is continuously working with business development to find suitable out-licensing solutions with other pharmaceutical companies.

FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se, is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se.

Attachments

AlzeCure presents positive preclinical efficacy data for the TrkA-NAM pain project